Trial reportBMC nephrology2014
Blood and breath profiles of volatile organic compounds in patients with end-stage renal disease.
Trial report in BMC nephrology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 36 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
36 citing papers in PubMed, 85 citations in OpenAlex.
- Comprehensive Two-Dimensional Gas Chromatography-Mass Spectrometry Analysis of Exhaled Breath Compounds after Whole Grain Diets.Molecules (Basel, Switzerland) · 2021Trial
- Protocol for tumor detection in mice using β-glucuronidase targeted breath analysis.STAR protocols · 2026Article
- Cyclohexanone and metabolites exposure in critically Ill neonates and children.Pediatric research · 2025Article
- Exploring exhaled volatile organic compounds as potential biomarkers in anti-MDA5 antibody-positive interstitial lung disease.Molecular and cellular biochemistry · 2025Article
- Evaluation of urinary volatile organic compounds as a novel metabolomic biomarker to assess chronic kidney disease progression.BMC nephrology · 2024Article
- Breath Analysis: Identification of Potential Volatile Biomarkers for Non-Invasive Diagnosis of Chronic Kidney Disease (CKD).Molecules (Basel, Switzerland) · 2024Observational
- Combination of real-time and hyphenated mass spectrometry for improved characterisation of exhaled breath biomarkers in clinical research.Analytical and bioanalytical chemistry · 2024Article
- Improved isoprene detection performance of Si-doped WORSC advances · 2024Article
- Identification of Volatile Markers of Colorectal Cancer from Tumor Tissues Using Volatilomic Approach.Molecules (Basel, Switzerland) · 2023Article
- Exploration of Potential Breath Biomarkers of Chronic Kidney Disease through Thermal Desorption-Gas Chromatography/Mass Spectrometry.Metabolites · 2023Article
- Smelling the Disease: Diagnostic Potential of Breath Analysis.Molecular diagnosis & therapy · 2023Review
- Unraveling the potential of breath and sweat VOC capture devices for human disease detection: a systematic-like review of canine olfaction and GC-MS analysis.Frontiers in chemistry · 2023Review
- Validation of the novel transdermal arterial gasotransmitter sensor (TAGSSensing and Bio-Sensing Research · 2022Article
- A Bilayer SnOBiosensors · 2022Article
- The Potential Use of Volatile Biomarkers for Malaria Diagnosis.Diagnostics (Basel, Switzerland) · 2021Review
- The Role of Protein Adduction in Toxic Neuropathies of Exogenous and Endogenous Origin.Toxics · 2021Review
- Induced volatolomics of pathologies.Nature reviews. Chemistry · 2021Review
- Comparison of volatile organic compound profiles in exhaled breath versus plasma headspace in different diseases.Journal of breath research · 2020Article
- Emerging non-invasive detection methodologies for lung cancer.Oncology letters · 2020Review
- Applications of Near Infrared Photoacoustic Spectroscopy for Analysis of Human Respiration: A Review.Molecules (Basel, Switzerland) · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 2 countries.
Funding
Abstract
backgroundMonitoring of volatile organic compounds (VOCs) in exhaled breath shows great potential as a non-invasive method for assessing hemodialysis efficiency. In this work we aim at identifying and quantifying of a wide range of VOCs characterizing uremic breath and blood, with a particular focus on species responding to the dialysis treatment.
methodsGas chromatography with mass spectrometric detection coupled with solid-phase microextraction as pre-concentration method.
resultsA total of 60 VOCs were reliably identified and quantified in blood and breath of CKD patients. Excluding contaminants, six compounds (isoprene, dimethyl sulfide, methyl propyl sulfide, allyl methyl sulfide, thiophene and benzene) changed their blood and breath levels during the hemodialysis treatment.
conclusionsUremic breath and blood patterns were found to be notably affected by the contaminants from the extracorporeal circuits and hospital room air. Consequently, patient exposure to a wide spectrum of volatile species (hydrocarbons, aldehydes, ketones, aromatics, heterocyclic compounds) is expected during hemodialysis. Whereas highly volatile pollutants were relatively quickly removed from blood by exhalation, more soluble ones were retained and contributed to the uremic syndrome. At least two of the species observed (cyclohexanone and 2-propenal) are uremic toxins. Perhaps other volatile substances reported within this study may be toxic and have negative impact on human body functions. Further studies are required to investigate if VOCs responding to HD treatment could be used as markers for monitoring hemodialysis efficiency.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.